Tradestie Institutional Equity Comparison Engine
ACCL vs SBC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SBC Overall Edge
SBC Captures Institutional Edge (3โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to SBC Medical Group Holdings Incorporated Common Stock (SBC) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, ACCL trades at N/M Forward P/E with 4.5% operating margin (+11.3% YoY revenue) versus SBC at 13.6x Forward P/E and 37.3% operating margin (+13.4% YoY). In options structure, ACCL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SBC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
SBC
ACCL N/M vs SBC 13.6x Fwd P/E
Growth & Margin Winner
SBC
Op Margin 4.5% vs 37.3% ยท YoY +11.3% vs +13.4%
Momentum & Technical Winner
SBC
1Y -42.4% vs +91.1% ยท 52W Pos 30% vs 79%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ACCL
US Equity
ACCL
Institutional Equity
$2.36
-0.84% 1D
Market Cap
$33.5M
1M Return
-12.26%
1Y Return
-42.44%
Forward P/E
N/M
Unified AI Score
63.4 / 100
BUY
Tech 68.0
Fund 58.0
Flow 50.0
Mom 60.0
SBC
NASDAQ
SBC Medical Group Holdings Incorporated Common Stock
Services-Offices & Clinics Of Doctors Of Medicine
$6.42
-12.65% 1D
Market Cap
$549.2M
1M Return
+24.42%
1Y Return
+91.07%
Forward P/E
13.6x
Unified AI Score
47.6 / 100
HOLD
Tech 15.0
Fund 39.0
Flow 50.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ACCL -42.44%
SBC +91.07%
Spread: +134.74 pp (SBC Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ACCL TTM Op. Margin: 4.5%
SBC TTM Op. Margin: 37.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACCL vs SBC. Trailing 12-month operating profitability (ACCL 4.5% vs SBC 37.3%) and valuation multiples (ACCL N/M vs SBC 13.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ACCL | SBC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $33.5M | $549.2M | Larger Scale | SBC |
| Trailing P/E Ratio Valuation | 120.0x | 11.4x | Lower Multiple | SBC |
| Forward P/E Ratio Valuation | N/M | 13.6x | Lower Multiple | SBC |
| Revenue Growth (YoY) Growth | +11.3% | +13.4% | Higher Growth | SBC |
| Operating Margin (TTM) Profitability | 4.5% | 37.3% | Higher Margin | SBC |
| Net Profit Margin Profitability | 5.5% | 28.0% | Higher Margin | SBC |
| Return on Equity (ROE) Capital Efficiency | 7.0% | 18.9% | Higher ROE | SBC |
| 52-Week Range Position Momentum | 30% ($1โ$5) | 79% ($3โ$7) | Stronger Trend | SBC |
| Beta / 30D Volatility Risk Regime | -0.20ฮฒ ยท 60% Vol | 0.65ฮฒ ยท 150% Vol | Lower Realized Risk | ACCL |
| Unified Institutional Score Composite Signal | 63.4 / 100 (BUY) | 47.6 / 100 (HOLD) | Higher Composite | ACCL |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ACCL vs SBC Buy Guide
ACCL
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
SBC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ACCL nor SBC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.